Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference
Rhea-AI Summary
Upstream Bio (Nasdaq: UPB) will present new Phase 2 VIBRANT data for verekitug at the American Thoracic Society (ATS) 2026 International Conference in Orlando on May 18, 2026. Two posters (P1397, P1398) by Joseph K. Han, MD, report clinical effects in CRSwNP with comorbid asthma and impacts on nasal and blood biomarkers.
The presentations cover verekitug as a thymic stromal lymphopoietin (TSLP) receptor antagonist and include biomarker and clinical outcome data from the VIBRANT trial.
Positive
- None.
Negative
- None.
News Market Reaction – UPB
In the Apr 17 session, UPB declined 1.09%, reflecting a mild negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Clinical trial Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 26 | VIBRANT analyses | Positive | +2.1% | Additional Phase 2 VIBRANT CRSwNP analyses in late-breaking AAAAI poster. |
| Feb 11 | VALIANT top-line data | Positive | -47.2% | Positive Phase 2 VALIANT severe asthma results with significant AAER reductions. |
| Sep 02 | VIBRANT top-line data | Positive | +18.3% | Phase 2 VIBRANT CRSwNP trial met primary and key secondary endpoints. |
| Jul 08 | VENTURE trial start | Positive | -0.7% | First patient dosed in Phase 2 COPD trial expanding verekitug indications. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Clinical trial headlines have produced mixed reactions: strong gains on some VIBRANT data but sharp selloffs on VALIANT results, with an average move of -6.89% across recent trial-related releases.
Over the past year, UPB has issued several clinical trial updates on verekitug across asthma, CRSwNP, and COPD. Positive top-line Phase 2 results in CRSwNP on Sep 2, 2025 drove a +18.27% move, while strong VALIANT asthma data on Feb 11, 2026 coincided with a -47.18% decline. Additional VIBRANT analyses on Feb 26, 2026 and the COPD VENTURE initiation on Jul 8, 2025 saw modest price shifts. Today’s conference-focused VIBRANT update fits into this pattern of frequent data and presentation milestones.
Key Terms
thymic stromal lymphopoietin medical
tslp medical
receptor antagonist medical
chronic rhinosinusitis with nasal polyps medical
biomarkers medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced two upcoming poster presentations at the American Thoracic Society (ATS) 2026 International Conference in Orlando, FL, on Monday, May 18, 2026. The presentations feature new data from the Phase 2 VIBRANT trial evaluating verekitug, the only known antagonist to the thymic stromal lymphopoietin (TSLP) receptor currently in clinical development, in chronic rhinosinusitis with nasal polyps (CRSwNP). The data to be presented include the clinical effect of verekitug in participants with CRSwNP and comorbid asthma, as well as its impact on nasal and blood biomarkers.
Presentation details:
- Presentation Title: Verekitug, a Thymic Stromal Lymphopoietin Receptor Antagonist, Administered in Participants with Chronic Rhinosinusitis with Nasal Polyps and Comorbid Asthma in the VIBRANT Trial
Presenting Author: Joseph K. Han, MD, Old Dominion University
Poster Board Number: P1397
Session: B32 – Rise of the Biologics: A New Hope for Breathing Easier
Presentation Date and Time: Monday, May 18, 2026 – 11:30 AM – 1:15 PM ET
- Presentation Title: Verekitug, a Thymic Stromal Lymphopoietin Receptor Antagonist, in Chronic Rhinosinusitis with Nasal Polyps: Effect on Type 2 Inflammatory Biomarkers in the VIBRANT Trial
Presenting Author: Joseph K. Han, MD, Old Dominion University
Poster Board Number: P1398
Session: B32 – Rise of the Biologics: A New Hope for Breathing Easier
Presentation Date and Time: Monday, May 18, 2026 – 11:30 AM – 1:15 PM ET
About Upstream Bio
Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist currently in clinical development that targets and inhibits the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. The Company has advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma, and chronic obstructive pulmonary disease (COPD). Upstream Bio’s team is committed to maximizing verekitug’s unique attributes to address the substantial unmet needs for patients underserved by today’s standard of care. To learn more, please visit www.upstreambio.com.
Investor and Media Contact:
Meggan Buckwell
Director, Corporate Communications and Investor Relations
ir@upstreambio.com
